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The ubiquitous metabolic intermediary and nucleoside adenosine is a “master regulator”
in all living systems. Under baseline conditions adenosine kinase (ADK) is the primary
enzyme for the metabolic clearance of adenosine. By regulating the availability of
adenosine, ADK is a critical upstream regulator of complex homeostatic and metabolic
networks. Not surprisingly, ADK dysfunction is involved in several pathologies, including
diabetes, epilepsy, and cancer. ADK protein exists in the two isoforms nuclear ADK-L,
and cytoplasmic ADK-S, which are subject to dynamic expression changes during brain
development and in response to brain injury; however, gene expression changes of
the Adk gene as well as regulatory mechanisms that direct the cell-type and isoform
specific expression of ADK have never been investigated. Here we analyzed potential
gene regulatory mechanisms that may influence Adk expression including DNA promoter
methylation, histone modifications and transcription factor binding. Our data suggest
binding of transcription factor SP1 to the Adk promoter influences the regulation of Adk
expression.
Keywords: adenosine kinase, specificity protein 1, rat, brain, development, epigenetic
INTRODUCTION
Adenosine kinase (ADK; EC 2.7.1.20) is an evolutionarily conserved phosphotransferase
converting the purine ribonucleoside adenosine into 5′-adenosine-monophosphate (AMP) (Park
and Gupta, 2008). This enzymatic reaction plays a fundamental role in determining the tissue
tone of adenosine, which fulfills essential functions as a homeostatic and metabolic regulator in
all living systems (Boison, 2013). ADK is the main enzyme in adenosine metabolism under baseline
conditions and crucial to maintain adenosine homeostasis. ADK activity keeps adenosine levels
low. Slight changes in enzyme activity result in major changes of adenosine concentration. Thereby,
ADK has key regulatory functions in different cellular processes: As a central sensor and regulator
of energy homeostasis its enzymatic activity is regulated by AMP, ADP, and ATP. Adenosine
plays a key role in enzyme catalysis as part of the coenzymes nicotinamide adenine dinucleotide
(NAD) and flavin adenine dinucleotide (FAD) (Denessiouk et al., 2001). It impacts intracellular
signaling through four different types of adenosine receptors, which combine to regulate the
second messenger cAMP (Fredholm et al., 2000). In the nucleus, ADK is a core element of nucleic
acid metabolism and a regulator of cell proliferation (Ethier and Dobson, 1997; MacLaughlin
et al., 1997). It is further an important regulator of epigenetic processes through its link to the
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transmethylation pathway (Boison et al., 2002b; Kobow and
Blumcke, 2012; Williams-Karnesky et al., 2013). Therefore, tight
regulation of ADK expression and activity becomes a necessity
and it is not surprising that several pathologies such as epilepsy,
diabetes or cancer are linked to ADK dysfunction (Pawelczyk
et al., 2000; Saitoh et al., 2004; Duarte et al., 2006; Sakowicz-
Burkiewicz et al., 2006; Giglioni et al., 2008; Li H. et al.,
2008; Aronica et al., 2011; Masino et al., 2011; Tsuchiya et al.,
2012).
During early postnatal rodent brain development Adk
protein expression undergoes a coordinated developmental shift
from a predominantly neuronal to a predominantly astrocytic
expression pattern (Fedele et al., 2005; Studer et al., 2006).
Adk exists in two isoforms: The long nuclear isoform Adk-
L may play a specific role during developmental processes
in the brain, presumably as epigenetic regulator, whereby
Adk-L drives the flux of methyl-groups through the DNA
transmethylation pathway. In contrast, the short cytoplasmic
isoformAdk-S regulates the extracellular tissue tone of adenosine
and thereby the degree of adenosine receptor activation (Boison,
2013).
Despite the dynamic changes in cell-type and isoform specific
expression patterns of Adk, the transcriptional regulation of
the Adk gene remains enigmatic. Here we first characterized
and quantified developmental changes in the cell-type and
isoform specific generation of Adk transcripts during early
postnatal brain development in rat. Coordinated changes
in transcription factor binding together with epigenetic
mechanisms may play a role in brain development (Bonasio
et al., 2010). Therefore, we analyzed transcription factor
binding as well as different epigenetic mechanisms including
DNA methylation and histone modification at two different
developmental time points representing the immature vs.
mature adenosine system (P4 and P14) in order to understand
their possible implication in the regulation of Adk. We found
striking developmental changes in isoform specific Adk
transcription, characterized by developmental downregulation
of nuclear Adk-L transcripts in neurons and upregulation of
cytoplasmic Adk-S transcripts in astrocytes. These coordinated
developmental changes in Adk gene transcription were in
part facilitated through transcription factor Specificity protein
1 (SP1), but according to our data not based on epigenetic
mechanisms.
MATERIALS AND METHODS
Animals
Wild-type 4 and 14 day old male and female Wistar rats (Charles
River, Sulzfeld, Germany) were used. All rats in the present
study were bred and maintained at the local animal center in
accordance with the guidelines of the European Federation for
Laboratory Animal Science Associations (Directive 2010/63/EU)
and with the German Animal Welfare Act. The study was
approved by the local animal care and use committee (TS
1/13). Animals were housed in breeding cages under controlled
environmental conditions (12 h light/dark cycle, 20–23◦C, 50%
relative humidity, drinking and feeding ad libitum).
Preparation of Cell Suspensions and
Individual Cell Populations
Rats were anesthetized with isoflurane (CP-Pharma, Burgdorf,
Germany), decapitated, and skulls opened. Whole brain
was removed and placed into a cold petri dish containing
hippocampus dissection buffer (HDB; 6 mg/ml glucose, 10 mM
saccharose, 25 mM HEPES, and 5 mM NaHCO3 in HBSS [w/o
MgCl2, CaCl2; Life Technologies, Darmstadt, Germany]) until
preparation. Preparation of cell suspensions was performed as
described elsewhere with modifications (Yang et al., 2010). In
brief, hippocampi of each hemisphere were resected and placed
into a cold HDB containing petri dish. Hippocampi were washed
3 times with HDB, then transferred into an enzymatic tissue
dissociation solution containing 0.01% DNase I, 0.1% dispase II,
0.01% papain (all Roche, Mannheim, Germany) and 12.5 mM
MgSO4 in HBSS and mechanically dissociated using a brain
specific program of the gentleMACS Octo Dissociator (Miltenyi
Biotec, Bergisch Gladbach, Germany). Afterwards the tissue was
incubated at 37◦C for 30 min, followed by another mechanical
dissociation step with the gentleMACS Octo Dissociator and
centrifugation at 800 rpm for 5 min at room temperature.
The suspension was gently triturated 5 times in serum-free
Neurobasal-A Medium (Life Technologies) supplemented with
2% B27 (Life technologies) and passed through a sterile nylon
strainer (70 µm). HDB containing 4% bovine serum albumin
(BSA; Amresco, Solon, USA) was added and the suspension
was centrifuged at 1100 rpm for 8 min at room temperature
to remove cell debris. Cell suspensions were then pre-plated
onto an uncoated flask and incubated at 37◦C in 5% CO2 for
1 h. During this time glial cells settled down and adhered to the
bottom of the flask, while neurons remained in the supernatant.
After pre-plating, the supernatant was collected and centrifuged
at 800 rpm for 8 min at room temperature. For gene expression
analyses glial cells were detached from the flask and centrifuged
at 800 rpm for 8 min at room temperature. Cell pellets were used
for subsequent processing.
Gene Expression Analysis
Hippocampi from 6 to 7 rat pups were pooled, neuronal and
glial cells isolated, and total RNA extracted from each cell pellet
using TRIzol Reagent (Life Technologies) according to the
manufacturer’s instructions with the modification to completely
dry the pellet at 56◦C for 1 h, and followed by DNase treatment
(Life Technologies) to avoid contamination with genomic
DNA. First-strand cDNA synthesis was performed using the
SuperScript II Reverse Transcriptase Kit (Life Technologies)
according to the manufacturer’s instructions. Quantitative
real-time PCR was performed using the 7500 Fast Real-Time
PCR System (Life Technologies) with Power SYBR Green PCR
Master Mix (Life Technologies) as fluorescent dye according to
the manufacturer’s protocol. The following primers were used
to selectively amplify each ADK isoform and both isoforms
at the same time: AdkRT_1 fw- CCAGAAGCGCTGAGTGA
AAAT, rev- GTCTTCGGCCAAGATCTGGT; AdkRT_2 fw-
ATGACGTCCACCAGTGAAAAT, rev- GTCTTCGGCCAAG
ATCTGGT; AdkRT_3 fw- GTGGCAACCGGTCTCTTGTT,
rev- AAACTCTGGCTTTCTCTACCAA; GAPDH fw- GGC
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 October 2016 | Volume 9 | Article 99
Kiese et al. Adk Regulation in Brain Development
TGGCATTGCTCTCAATG, rev- CATGTAGGCCATGAGG
TCCA. GAPDH quantification was used as internal reference
gene for normalization. Fold differences of mRNA levels were
calculated using the 11Ct method. No-template controls for
each primer were included on every plate and melt curve analysis
was performed to exclude unspecific amplification. All PCR
reactions were repeated three independent times (i.e., 3 technical
replicates) from three different cell preparations (i.e., 3 biological
replicates).
Chromatin Immunoprecipitation Assay
For ChIP experiments hippocampi of rat pups derived from
one litter were used for preparation and cell suspensions
were pooled for fixation. Chromatin immunoprecipitation was
performed according to the X-ChIP protocol from Abcam with
some modifications. In detail, neuronal cell pellets were cross-
linked in 0.8% formaldehyde for 10 min at room temperature.
The crosslinking reaction was stopped by adding glycine to a
final concentration of 0.125 M and centrifuged at 1000 rpm
for 8 min at 4◦C. Pellet was washed twice in cold PBS and
snap frozen in liquid nitrogen. Cells were lysed in SDS-lysis
buffer (50mM Tris-HCl [pH 8.0], 10 mM EDTA dihydrate,
1% SDS) for 1 h and lysis was facilitated by passing the lysate
through a 0.4mm needle several times. The lysate was sheared
using a Diagenode Bioruptor on high power for 4 × 5 cycles
(30 s on-off). Equal amounts of chromatin lysate (2 µg) were
diluted 10 times with RIPA buffer (50 mM Tris-HCl [pH8:0],
150 mM NaCl, 2 mM EDTA dihydrate [pH8.0], 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS) and pre-cleared with
Dynabeads Protein G magnetic beads (Life Technologies) for
1 h. Immunoprecipitation was performed overnight with the
corresponding primary IgG antibody along with the Dynabeads
Protein G magnetic beads. Immune complexes were washed
three times with ChIP wash buffer (0.1% SDS, 1% Triton X-
100, 2 mM EDTA dihydrate [pH8.0], 150 mM NaCl, 20 mM
Tris-HCl [pH8.0]), once with ChIP final wash buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA dihydrate [pH8.0], 500 mM
NaCl, 20 mM Tris-HCl [pH8.0]) and were then eluted from
the beads with 120 µl elution buffer (1% SDS, 0,1 M NaHCO3,
pH9.0). Protein-DNA cross-links were reverted by overnight
incubation at 65◦C and DNA was extracted using the QIAquick
PCR Purification Kit (Qiagen) according to the manufacturer’s
protocol. DNA quantification was done by quantitative real-
time PCR using the same protocol as mentioned above. The
following antibodies were used: 4 µg H3K9ac (ab10812, abcam,
Cambridge, UK), 4 µg H3K4me3 (07–473, Millipore, Molsheim,
France), 10 µg H4ac (06–866, Millipore), 10 µl H3S10phK14ac
(07–081, Millipore), 4 µg H3K27me3 (07–449, Millipore), 8 µg
SP1 (17–601, Millipore) and IgG (Millipore). Primers used for
amplification of immunoprecipitated DNA are summarized in
Table 1. Hist1H4B was used as control primer for normalization
for H3K9ac, H3K4me3, H3S10phK14ac; MyoD for H3K27me3
and DHFR for SP1. All steps were performed at 4◦C up
to and including the immunoprecipitation step. PBS, SDS-
Lysis buffer and RIPA buffer were supplemented with protease
inhibitors (EDTA-free protease inhibitor cocktail tablets; Roche)
andHDAC inhibitors (sodium butyrate; Calbiochem, Darmstadt,
Germany) immediately before application. Nonspecific IgG
TABLE 1 | Genomic DNA primers used for quantitative real-time PCR to
amplify immunoprecipitated DNA.
PrimerID Forward primer Reverse primer
Adk1a AAACCTGGGGGCTGACAAGTT ACACCCGGGCTTCCTAGTCA
Adk1b TCTGTTCCCCGGCTTTTGAGAT CCTCGGAGGCTGCTAGTCA
Adk1c GGTCAGCGGGACTAGAAAGA AAGGGACCCAAAACGCAGTTA
Adk1d CAGACGCGCGTAGAGCCAAT TCACCGCGGTTTGGCTCTGC
Adk1e GCCAAACCGCGGTGAGAGT CCCACGAACGCAGTCACCAT
Adk1f TGGTCCGGGGGCTGAGTCTT GGGCGCCTTCCCGCTAAATA
Adk2a TGAGTGAGGCCCTCATACTCA ACATCCAGCGGCATTCATTTAC
Adk2b CAGCTGTTGCCACGCTTATAGT CAACCGGGTTCGCAGTCACA
Adk2c TGAGGCGGGCACTCAACCTT CACGCGGGCTAGCTGACCA
Adk2d GCGCTCTCCGTCGCTGAGT GGCCGCCCTCTGCTTACCT
Adk2e GCGGGACCGGTAGGTGAAGT AGGGGGAACGTCCGACAGAA
Adk2f TGGCCTTGCCCACTTTATTTAG CTCATGGCCCCAAATTACTTC
Hist1H4B CGGCCTCATCTACGAGGAGA CTTAGCCGCCGAAGCCATAGA
MyoD GGCTGTCCACCCCAGTTTGAATA GACGAAGTGGGCAAGAGACAGT
Dhfr CGCGCGGCCGCACTTCCT GGCCCGCCGCGCATCCTA
antibody was included in each ChIP as a negative control
to exclude unspecific interaction. All ChIP experiments were
repeated three independent times (i.e., 3 technical replicates) for
each antibody out of 3 different cells pools (i.e., 3 biological
replicates). Subsequent qPCR was also performed in triplicates.
Bisulfite Sequencing
Genomic DNA was extracted from neuronal cell pellets using the
QIAamp DNA Micro Kit (Qiagen, Hilden, Germany), followed
by bisulfite conversion of 1 µg of genomic DNA using the
EpiTect Bisulfite Kit (Qiagen) according to the manufacturer’s
protocol. Regions of interest were amplified using the TaKaRa
EpiTaq HS Kit (TaKaRa Clontech, Otsu, Japan) and cloned
using the TOPO TA Cloning Kit (Life Technologies) doing
blue/white screening. White colonies were selected and grown
in LB medium overnight. The plasmid was purified using the
GeneJET Plasmid Miniprep Kit (Thermo Scientific, Darmstadt,
Germany) and clones were sequenced by the Sanger sequencing
method (GATC Biotech, Cologne, Germany). Sequences were
quality controlled and aligned using the CLC sequence viewer
(CLC bio). The following primers were used to amplify bisulfite
converted DNA at the promoter region of the first ADK isoform:
AdkBB_1.1 fw AGGGATATTTTTGGAGTTTTAGAGAG,
rev-TCAAAAAATACCAATCTCCCTATTC; AdkBB_1.2 fw-
AATAGGGAGATTGGTATTTTTTGAG, rev-TTCCACCTTAA
ACTTCTTAAACTTC; AdkBB_1.3 fw-AGTTTAAGAAG
TTTAAGGTGGAAG, rev- AAAATCCAAAACCAAAAA
ACACTAA, and at the promoter region of the second isoform:
AdkBB_2.1 fw-AGTTTGAGGTTTTTTAGGTGGTTG, rev
ATCCTAATAACCACCTCCCCTTAC; AdkBB_2.2 fw GTTA
GTTTTTTTGTTGGTTAGTTAGTT, rev CAATAATTCTCCCT
AAATCTACAAACTC.
Luciferase Assay
A ∼500 bp fragment of the rat Adk-L minimal promoter
including transcription start and ATG triplet (start codon)
and an analog fragment with mutated SP1 binding sites,
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both flanked by restriction sites for Nhe1 and EcoRV (oligo
synthesized by Eurofins Genomics, Ebersberg, Germany), were
digested with respective restriction endonucleases (both New
England Biolabs, Frankfurt am Main, Germany) and cloned
into the pGL4.10 Firefly Luciferase vector (Promega, Mannheim,
Germany) to produce recombinant constructs (pGL4.Adk-
500 and pGL4.Adk-500mut). A construct derived from the
pGL4.10 vector containing the Herpes Simplex Virus Thymidine
kinase (HSV-TK) minimal promoter in front of the Firefly
Luciferase gene served as positive control (pGL4.TK). The
pRL-TKVector (Promega) encoding the Renilla Luciferase under
control of the HSV-TK promoter was used as transfection
control. pGL4.Adk-500 as well as pGL4.Adk-500mut vectors
were each co-transfected with the pGL4.TK reporter vector into
HEK293 cells, with control plasmids encoding Renilla Luciferase,
using Lipofectamine Transfection Reagent (Thermo Fisher
Scientific, Schwerte, Germany). 24 h following transfection HEK
cells were incubated for 3 h with different concentrations
of recombinant SP1 protein (Sigma-Aldrich, Taufkirchen,
Germany) in the growth medium. Luciferase activities were
assayed using the Dual-Luciferase Reporter Assay (Promega)
according to the manufacturer’s protocol. Thereby Firefly
Luciferase measurements were normalized to Renilla Luciferase
activity. All Luciferase assays were performed in triplicate.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows
version 17.0 and GraphPad Prism6. Differences in gene
expression and DNA methylation were compared using Mann-
Whitney test, whereas differences in transcription factor binding
and chromatin modifications were analyzed using Wilcoxon
matched-pairs test. Statistical significance of individual data pairs
was further determined using multiple t-test comparisons, one
per row (i.e., Holm-Sidak method). Data from reporter gene
assays was analyzed using Friedman statistic. A p value<0.05 was
considered significant. All data is presented as mean ± standard
deviation.
RESULTS
Dynamic Shifts of Adk Gene Transcription
during Early Postnatal Brain Development
To understand the molecular basis for dynamic changes in Adk
protein expression during early postnatal brain development
we quantified Adk gene expression at early developmental
time points in the rat. For experimental procedure see
Supplement Figure 1. To quantify cell-type and isoform specific
changes in Adk gene transcription we isolated hippocampal
neuronal and glial cell populations from rat pups at postnatal
days four (P4) and 14 (P14) for quantitative real-time PCR
analysis of the long and short isoforms Adk-L and Adk-S.
In hippocampal neurons we found a 2.5-fold decrease in
gene expression of the long Adk isoform between P4 and
P14 (p < 0.05), whereas the short isoform was not affected
(Figure 1A). In contrast, in glial cells, mRNA levels of the
short isoform significantly increased between P4 and P14
(Figure 1B), whereas gene expression of the long Adk isoform
was unaffected. These data demonstrate opposing directions
of the regulation of the two isoforms of Adk in neurons vs.
glia suggesting complex regulatory mechanisms of Adk gene
expression.
Impact of Histone Modifications on Adk
Gene Expression
We asked, whether chromatin modifications may play a role
in the regulation of Adk isoform expression. Chromatin
immunoprecipitation was carried out to evaluate different
modifications of histone H3 and H4 at the two promoter regions
of long and short Adk isoforms, respectively, using P4 and P14
rat hippocampal neurons. Antibodies directed against acetylated
histone H4 and H3 (H4Ac, H3K9Ac), phosphoacetylated H3
(H3S10phK14Ac), and trimethylation of lysine 4 or 27 of
histone H3 (H3K4me3, H3K27me3) were applied. Following the
enrichment step quantitative real-time PCR with Adk-specific
primers was performed to prove binding of histones with
respective modifications to the Adk promoters. The amplified
regions cover large parts of each promoter region (Adk-L:
−735 bp to +470 bp; Adk-S: −1043 bp to +1084 bp) as depicted
in Figures 2A, 3A.
We identified histone acetylation of histone H3 and H4 as well
as phosphoacetylation at histone H3 at the promoter regions of
both Adk isoforms in P4 and in P14 rat hippocampal neurons,
especially upstream to the TSS (Figures 2B, 3B). Additionally
there was trimethylation of lysine 4 of histone H3 at both Adk
promoters. Trimethylation of lysine 27 of histone H3 on the
other hand was neither found at the promoter of the long
isoform nor at the promoter of the short isoform. In summary,
we identified similar compositions of histone modifications at
the promoter of the long isoform as at the predicted promoter
of the short isoform in both P4 and P14 rat hippocampal
neurons.
Methylation Status of Adk Promoters in
Early Postnatal Brain Development
We next focused on promoter DNA methylation. The EMBOSS
Cpgplot tool was used for CpG island prediction. Two
consecutive CpG islands were identified around the TSS of the
long Adk isoform enclosing a region of 755 bp. Furthermore, a
single CpG island of 588 bp was predicted to be located within the
presumed promoter of the short Adk isoform (Figures 2A, 3A).
Harvested DNA from P4 and P14 rat hippocampal neurons
was used for amplification (subsequent to bisulfite treatment) and
sequencing of the rat Adk promoters including 5′ untranslated
region (UTR) and first exon of long (Pos. −588 to +298) and
short isoforms (Pos. −391 to +293), respectively. However,
both promoters were unmethylated in P4 as well as in P14 rat
hippocampal neurons (Figure 4).
Regulation of Adk Expression through
Transcription Factor SP1
In silico analysis of the two alternative Adk gene promoters,
which are anticipated to regulate Adk isoform expression,
identified CG boxes close to the transcription start for the
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FIGURE 1 | Adk gene expression in early postnatal brain development. (A) Adk gene expression of long and short Adk isoforms separately as well as total Adk
expression in rat hippocampal neurons and (B) in rat hippocampal glial cells at postnatal days 4 and 14 (P4 and P14, respectively) is shown. Adk gene expression was
calculated relative to internal reference gene GAPDH. Neuronal and glial Adk gene expression at P4 was normalized to respective expression at P14, which was
always set at 100%. Adk-L - long Adk isoform; Adk-S - short Adk isoform. *indicates significance.
long, but not the short rat Adk isoform (Figure 5). These
elements can be bound by specificity protein 1 (SP1; Figure 5A
upper panel). In order to analyze SP1 binding to the Adk-L
promoter, chromatin immunoprecipitation was performed in P4
and P14 rat hippocampal neurons. We identified SP1 binding
in both P4 and P14 rat hippocampal neurons around the
transcription start site (TSS; Figure 5A lower panel). Wilcoxon
rank test identified no significant difference in SP1 binding
to the regulatory promoter region of the long Adk isoform
between the two groups. Multiple t-test analysis for each data
pair (P4 vs. P14) along the promoter identified significantly
increased SP1 binding at position −102 to +50 relative to
the TSS in P14 neurons (Holm-Sidak method, p=0.0098). This
region covers the three putative SP1 binding sites (Figure 5A
upper panel).
To prove binding of SP1 to the Adk-L promoter and thus
SP1-mediated suppression of gene expression we transiently
transfected HEK293 cells with reporter plasmids containing
Luciferase under the control of the minimal Adk-L promoter
covering∼500 bp around the TSS including all three SP1 binding
sites (Adk-500; Figure 5B). Reporter plasmids containing the
Herpes Simplex Virus thymidine kinase minimal promoter
(HSV-TK) served as positive control. Assessment of Luciferase
activity revealed promoter activity for the chosen genomic region
(Figure 5C). Promoter activity for the Adk-500 promoter was
slightly lower than HSV-TK promoter activity in HEK293 cells.
Incubation with increasing concentrations of recombinant SP1
in the culture medium over 3 h reduced promoter activity
significantly suggesting concentration dependent regulation
of Adk-L promoter activity by SP1 binding (Friedman test,
p = 0.018, Figure 5C). Upon mutation of all three SP1
binding sites activity of the Adk-L minimal promoter was
restored back to control levels and entirely independent
of supplemented SP1 (pGL4.Adk-500mut; Figure 5C). Our
experimental finding on transcription factor binding validate in
silico data on the existence of a second active Adk promoter
(Cui et al., 2011). Differential binding of SP1 to the Adk-
L promoter in hippocampal neurons of P4 and P14 rats
seemed to have contributed to the dynamic Adk expression
pattern.
DISCUSSION
Adk is an important neurodevelopmental gene, with broad
implications for brain homeostasis and function. Adk-null
mice have transmethylation deficits, develop hepatic steatosis,
and die during early postnatal development (Boison et al.,
2002b). Likewise, ADK-deficient patients have transmethylation
deficits and develop hepatic encephalopathy (Bjursell et al.,
2011). Conditional ADK mutants suggest a functional link
between adenosine homeostasis and higher order brain function
(Fedele et al., 2005; Pignataro et al., 2007; Yee et al., 2007;
Li T. et al., 2008; Palchykova et al., 2010; Shen et al.,
2011; Wu et al., 2013; Diógenes et al., 2014). Moreover,
ADK dysfunction is involved in several neurological and
neuropsychiatric pathologies whereas corrective reconstruction
of adenosine signaling is of therapeutic value (Boison et al.,
2002a, 2012; Boison and Aronica, 2015). Given the translational
significance of ADK-based regulation of adenosine homeostasis,
understanding the mechanisms underlying Adk gene regulation,
and hence the regulation of adenosine metabolism, is of
practical value for clinical translation. Our findings indicate
that Adk gene expression is tightly controlled during early
postnatal brain development both in a cell-type and isoform
selective manner. Several aspects of our work warrant further
discussion.
Adk Gene Structure
The Adk gene is one of the largest genes in the mammalian
genome (> 350 kb in mice, rats, and humans). Its coding
sequence is highly conserved in vertebrates. The rat Adk gene,
as all known mammalian Adk genes, consists of 11 short exons
and exceptionally large introns. There are two ADK isoforms,
long and short (ADK-L and ADK-S), expressed in mammalian
cells (Cui et al., 2009). Both isoforms are identical except for
the first exon. The first exon of the short isoform is located
in the intronic sequence between the first and second exon of
the long isoform. Both isoforms are most likely regulated by
two independent promoters (Cui et al., 2009). The promoter
of the first isoform is a bidirectional promoter regulating
also the expression of the clathrin adaptor subunit µ3A gene
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FIGURE 2 | Impact of epigenetic chromatin modifications on Adk-L promoter activity in P4 and P14 rat hippocampal neurons. (A) Promoter region of the
long Adk isoform was analyzed from pos. −735 to + 470 relative to the TSS. (B) Activating histone modifications were identified at the Adk-L promoter in both P4 and
P14 hippocampal neurons, including acetylation of H3 and H4, as well as H3 phosphoacetylation and lysine 4 trimethylation, with a relative sparing of the TSS. There
was no evidence for repressive H3K27 trimethylation. Upper right corner of each diagram with insets showing enrichment of positive controls for each antibody
presented as percent of the total input chromatin (% input). Adk-L promoter, promoter regulating long Adk isoform expression; ChIP, chromatin immunoprecipitation;
H3K9ac, acetylation of lysine (K) 9 of histone H3; H4ac, pan-acetylation of histone H4; H3S10phK14ac, phosphoacetylation of histone H3 targeting Serine (S) 10 and
Lysine (K) 14; H3K4me3, trimethylation of lysine (K) 4 of histone H3; H3K27me3, trimethylation of lysine (K) 27 of histone H3; TSS, transcriptional start site.
(Ap3m1) lying upstream of the Adk gene (Cui et al., 2009).
Genomic organization and linkage of the Ap3m1 and Adk genes
via a bidirectional promoter has been validated by deletion
mutants of cultured Chinese hamster cells (Singh and Gupta,
2004) and is conserved between species, e.g., rats, mice and
humans (see ENSEMBL genome browser; Yates et al., 2016).
However, the promoter of the second isoform was identified
only in silico, upstream of the first exon of the short isoform (in
the intronic region) containing a CpG island and transcription
factor binding sites (Cui et al., 2009). Here we provide the first
experimental evidence for the existence of a second promoter
as we identified specific histone modifications and selective
transcription factor binding sites indicative of an active gene
promoter.
Coordinated Changes in Adk Gene
Expression
There is strong evidence that temporal and spatial ADK isoform
expression is highly regulated. For mammalian brain ADK
protein a dramatic switch from neuronal toward glial, and
long toward short Adk isoform expression has been described
during early postnatal brain development (Studer et al., 2006;
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FIGURE 3 | Impact of epigenetic chromatin modifications on Adk-S promoter activity in P4 and P14 rat hippocampal neurons. (A) Promoter region of the
short Adk isoform was analyzed from pos. −1043 to +1084 relative to the TSS. (B) Enrichment of activating histone modifications at the Adk-S promoter in both P4
and P14 hippocampal neurons, including acetylation of H3 and H4, as well as H3 phosphoacetylation and lysine 4 trimethylation, particularly upstream of the TSS was
identified. No evidence for repressive H3K27 trimethylation. Adk-S promoter, promoter regulating short Adk isoform expression; ChIP, chromatin immunoprecipitation;
H3K9ac, acetylation of lysine (K) 9 of histone H3; H4ac, pan-acetylation of histone H4; H3S10phK14ac, phosphoacetylation of histone H3 targeting Serine (S) 10 and
Lysine (K) 14; H3K4me3, trimethylation of lysine (K) 4 of histone H3; H3K27me3, trimethylation of lysine (K) 27 of histone H3; Hist1H4B, Histone cluster 1, H4B;
MyoD, Myogenic differentiation 1; TSS, transcriptional start site.
Cui et al., 2009). In rodents the described changes occur
during the first three postnatal weeks, with major shifts in
hippocampal ADK protein expression occurring toward the
end of the first postnatal week. These coordinated changes on
the protein level suggest the existence of matching regulatory
mechanisms on the level of gene transcription. We therefore
analyzed Adk gene expression in the rat hippocampus at two
distinct developmental stages, an early time-point reflecting
largely neuronal ADK expression (P4) and a later time-point
reflecting largely astroglial ADK expression (P14). In line with
protein data (Studer et al., 2006) we provide evidence that at
P4 the Adk gene is predominantly expressed in hippocampal
neurons, whereas later at P14 it seemed to be predominantly
expressed in glial cells. Strikingly we found opposing shifts in
isoform expression in different cell types with downregulation
of the nuclear isoform in neurons and upregulation of the
cytoplasmic isoform in astrocytes during this developmental
time window. These findings suggest the need for specific
regulatory mechanisms governing cell-type and isoform selective
Adk gene expression. Those findings prompted our subsequent
evaluation of mechanisms implicated in the regulation of gene
expression.
Regulation by Epigenetic Modifications
To further delineate the mechanisms through which the switch
in Adk gene expression in the rodent brain is mediated, we
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FIGURE 4 | DNA promoter methylation. CpG methylation was analyzed using bisulfite sequencing following amplification and subcloning of the region of interest. A
minimum of three clones was analyzed per sample. Promoter regions were amplified from pos. −588 to +298 (long isoform) and pos. −391 to +293 (short isoform)
relative to TSS.
analyzed epigenetic chromatin modifications at the Adk-L and
Adk-S promoter region in rat hippocampal neurons at two
developmental stages that are characterized by stable neuronal
(P4) and stable astrocytic expression (P14) of Adk. Epigenetic
gene regulation is very complex, which ensures nuclear processes
(i.e., transcription, replication, DNA damage response) to be
directed to the required region of the genome at appropriate
time points mediating unique cellular responses and biological
outcomes. This same complexity is what makes analysis and
interpretation of epigenetic modifications difficult. However,
some signals are more understood than others, e.g., promoters
of active genes are commonly associated with acetylated H3K9
(H3K9ac) and H4. Likewise, phosphoacetylation of histone
H3 (e.g., H3S10phK14ac) concomitant with gene activation is
well established and has been observed at several inducible
genes (Clayton and Mahadevan, 2003). The mark H3K4me3 is
also found at active gene promoters as well as promoters of
genes that are poised for activation. In contrast, temporarily
inactive genes, such as in undifferentiated cells are marked
by H3K27me3, a mark of facultative heterochromatin, with or
without the transcriptionally permissive H3K4me3 (Bernstein
et al., 2006). We detected activating histone modifications
including H3K9Ac, H3S10phK14Ac, H4Ac, and H3K4me3 at the
promoter regions regulating Adk isoform expression in both P4
and P14 rat hippocampal neurons. Prevalence of histone H3 and
H4 acetylation as well as H3K4me3 provide a typical signature
for CpG island promoters (Guenther et al., 2007; Mikkelsen
et al., 2007). In the present study there was no experimental
evidence for repressive trimethylation of H3K27. In addition,
CpG islands embedded in the two Adk promoters were found to
be unmethylated, which is in concordance with previous findings
on the regulation of developmental genes (Weber et al., 2007;
Borgel et al., 2010; Numata et al., 2012). Taken together, our data
point to open chromatin structure within the Adk promoters in
both P4 and P14 rat hippocampal neurons. However, our analysis
covered only a small minority of all known histonemodifications,
which is why an influence of the histone code on differential
Adk isoform expression during brain development cannot be
excluded. Furthermore, we focused on the promoter region, but
did not analyze other regulatory elements such as enhancer,
silencer or insulator elements. In this context, it should be noted
that the Adk-L promoter is a bidirectional promoter, which
also controls transcription of a clathrin adaptor-related protein
complex subunit. Regulation of Adk expression by intragenic
signatures can also be anticipated. Since the Adk gene is an
evolutionary highly conserved gene containing extremely large
intronic sequences in higher eukaryotes, it is possible that these
sequences harbor regulatory elements to control Adk expression.
Interestingly, the Adk gene is much smaller in lower eukaryotes
suggesting that regulatory elements which are needed for tissue
and development-specific regulation in higher eukaryotes are
located in growing intronic sequences (Singh et al., 2001; Singh
and Gupta, 2004).
Regulation through Transcription Factor
Binding
Expression of eukaryotic genes is primarily controlled at the
level of transcription initiation, although in some cases it may
be attenuated and regulated at subsequent steps. Promoters
contain cis-acting sequences which serve as binding sites for a
wide variety of regulatory factors that control the expression
of individual genes. Here we performed in silico analysis of
the two Adk promoters and identified three putative binding
sites for specificity protein 1 (SP1) in close proximity to the
transcriptional start site (TSS) of the long Adk isoform. SP1
binds with high affinity to GC-rich motifs and regulates the
expression of a large number of genes involved in a variety of
processes including cell growth, apoptosis, and differentiation
(Wierstra, 2008). Previous Adk promoter studies have shown
that deletion of the first 200 bp upstream of the start codon
ATG lead to a 3-fold increased promoter activity, suggesting
inhibitory elements located in this region (Singh and Gupta,
2004). The significantly increased binding of SP1 to this
distinct part of the Adk-L promoter in P14 neurons points
to an inhibitory effect of SP1 binding on the expression of
the long Adk isoform. In fact, luciferase reporter gene (luc2)
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FIGURE 5 | Identification of transcription factor binding. (A) Upper panel: SP1 binding sites (indicated in red) at the amplified region of Adk 1d primers (indicated
in blue) around the TSS (pos. +1, bold). Lower panel: Binding of SP1 to the promoter region of the long Adk isoform are shown relative to a positive control primer in
P4 and P14 rat hippocampal neurons. The analyzed promoter region spanned over 1 kb between position −735 and +470 relative to the TSS. There is significant
enrichment of SP1 binding around the TSS of the Adk-L promoter in P14 rat hippocampal neurons, which may be implicated in the suppression of the long Adk
isoform. Inset displays enrichment of positive control for Sp1 antibody presented as percent of the total input chromatin (% input). (B) Luciferase assay was performed
to analyze the binding of SP1 to the Adk promoter and its impact on gene expression. Therefore, the Adk-L promoter including 1.000bp upstream the TSS was
subcloned in front of luciferase 2 (luc2) gene in the pGL4.10 vector and transfected into HEK293 cells. Transfected cells were incubated with increasing
concentrations of recombinant SP1 for 3 h and then used for luciferase activity measurements. (C) We identified a concentration dependent negative regulation of the
Adk-L promoter and luc2 gene through transcription factor SP1. Adk, Adenosine kinase; Adk-L promoter, promoter regulating expression of the long Adk isoform;
Ap3m1, adaptor-related protein complex 3, mu 1 subunit; ChIP, chromatin immunoprecipitation; CpG, cytosine guanine dinucleotide; DHFR, Dihydrofolate reductase;
kb, kilobase; SP1, specificity protein 1;TSS, transcriptional start site. *indicates significance.
under the control of the Adk-L promoter (500 bp upstream
the TSS) showed a concentration dependent effect of SP1
binding on luc2 gene expression in HEK cells, which could be
completely blocked by mutating SP1 binding sites. However,
there is also low, but present binding of SP1 to the Adk-L
promoter in rat P4 neurons. Since SP1 can activate and silence
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gene expression and is highly regulated by post-translational
modification, e.g., phosphorylation, sumoylation, proteolytic
cleavage, glycosylation, and acetylation (Wierstra, 2008), it might
be possible that additional mechanisms beyond SP1 binding itself
are involved in the fine tuning of Adk expression.
Conclusions and Outlook
We documented dynamic changes in Adk gene transcription
during early postnatal brain development. Two selective time
points were investigated, P4 and P14, respectively, flanking the
narrow time window when Adk expression changes from the
long neuronal to the short glial isoform. We identified altered
binding of transcription factor SP1 to the Adk-L promoter in
close proximity to the TSS. Despite previous reports linking
SP1 binding to downstream epigenetic changes we did not
find any alterations with regard to common activating and
silencing chromatin marks. Our data explain some mechanisms
underlying the temporal and spatial changes in Adk gene
expression in the postnatal rodent brain, but for obvious reasons
are non-exhaustive. Future studies need to be conducted to
further delineate the role of other epigenetic regulatory events
and the relevance of the time window investigated as well as
the potential implication of other, so far unconsidered, more
archaic regulatory mechanism outside epigenetics, e.g., through
the availability (excess or lack) of adenosine, to control Adk
gene expression. Such archaic mechanisms might be meaningful,
because the long Adk primary transcripts (>400,000 residues in
the rat) sequester significant amounts of adenosine, suggesting
that Adk gene transcription might be regulated by the availability
of adenosine, an interesting possibility that warrants further
exploration.
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